NVS.BA : Summary for NOVARTIS AG CEDEAR EACH REP 0.5 - Yahoo Finance

U.S. Markets closed

NOVARTIS AG CEDEAR EACH REP 0.5 (NVS.BA)


Buenos Aires - Buenos Aires Delayed Price. Currency in ARS
Add to watchlist
577.000.00 (0.00%)
At close: 1:48PM ART
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close577.00
Open577.00
Bid583.25 x
Ask0.00 x
Day's Range577.00 - 577.00
52 Week Range566.85 - 585.00
Volume336
Avg. Volume16
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Novartis' Acute Heart Failure Drug Fails in Late-Stage Study
    Zacks23 hours ago

    Novartis' Acute Heart Failure Drug Fails in Late-Stage Study

    Novartis AG (NVS) recently suffered a setback on the announcement of disappointing data from a phase III study, RELAX-AHF-2, on pipeline candidate serelaxin (RLX030).

  • American City Business Journalsyesterday

    Novartis cancer drug combo developed partly in Cambridge shows early promise

    An experimental cancer drug developed by Cambridge-based Novartis Institutes for BioMedical Research has been shown to destroy tumors in mice and keep them from returning when used in combination with an approved treatment. Scientists sought to test the drug, called ABL001, in combination with an FDA-approved drug sold by Novartis (NVS) as Tasigna, as a potential treatment for chronic myeloid leukemia, or CML. The combination therapy was shown to quickly eradicate tumor cells in mice, and to keep them from returning for at least three months after treatment was stopped, according to the paper.

  • Novartis Heart Drug Flops In Second Late-Stage Trial — As Expected
    Investor's Business Dailyyesterday

    Novartis Heart Drug Flops In Second Late-Stage Trial — As Expected

    Analysts expected Novartis' heart drug to fail in a late-stage trial, an analyst said Wednesday after the firm fulfilled that prediction.